santhera
Santhera announces Early Access Program by partner Sperogenix for DMD treatment
June 11, 2024Medical Communications DMD, Musculo-skeletal disorder, early access, muscular dystrophy, santhera
Santhera Pharmaceuticals has announced that its partner Sperogenix Therapeutics has launched a paid-for Early Access Program (EAP) for Agamree (vamorolone) …
Santhera gains MHRA approval for Agamree as treatment for Duchenne muscular dystrophy
January 12, 2024Medical Communications Agamree, Duchenne Muscular Dystophy, MHRA, Musculo-skeletal disorder, santhera
Santhera Pharmamceuticals has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved Agamree (vamorolone) in the UK …
Santhera closes exclusive license agreement with Catalyst Pharmaceuticals for Vamorolone
July 19, 2023Medical Communications License Agreement, Musculo-skeletal disorder, Vamorolone, catalyst, santhera
Santhera Pharmaceuticals has announced the closing of its exclusive North American license agreement for vamorolone with Catalyst Pharmaceuticals. The agreement …
Santhera and Catalyst Pharmaceuticals sign $231m license and collaboration deal
June 20, 2023Medical Communications Catalyst Pharmaceuticals, Rare Diseases, Vamorolone, licence and collaboration, santhera
Swiss specialty pharmaceutical company Santhera and US-based biopharmaceutical company Catalyst Pharmaceuticals have announced that they have signed an exclusive license …
Top Ten most popular articles on Pharmafile.com this week
February 2, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ablynx, Alzheimer's, Apotex, AstraZeneca, Brexit Health Alliance, CDC, Duchenne Muscular Dystrophy, EMA, Italy, Sanofi, amazon, brexit, santhera, top ten
It’s the first Friday of February, and it’s time for another recap of the top ten articles most popular with …
Santhera ‘surprised’ by European rejection of DMD drug
September 18, 2017Sales and Marketing Duchenne Muscular Dystrophy, biotech, drugs, pharma, pharmaceutical, santhera
Santhera Pharmaceutical has announced the EMA’s CHMP rejected its treatment for Duchenne muscular dystrophy (DMD) but revealed that it planned …
Shares drop at Santhera after FDA requires more trial data DMD drug
July 15, 2016Medical Communications, Research and Development Duchenne Muscular Dystrophy, FDA, santhera
Santhera Pharmaceuticals (SIX: SANN) has seen shares fall as much as 38% after the US Food and Drug Administration (FDA) …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
